Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI571 and PEG INTRON in Chronic Myeloid Leukemia
NCT00511121Phase 2Terminated
- Sponsor
- Alma Mater Studiorum – Università di Bologna
- Start
- Apr 2001
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons, Small Molecules
01
Overview
A Phase 2 trial of imatinib, peginterferon alfa-2b in chronic myeloid leukemia (CML), sponsored by Alma Mater Studiorum – Università di Bologna. Started Apr 2001; status: terminated.
02
Drugs
imatinibpeginterferon alfa-2b
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00511121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00511121.